Skip to main content

Table 3 Histologic abnormalities of study groups

From: Investigation of potential early Histologic markers of pediatric inflammatory bowel disease

 

IBD

Control

p value

Gastritis

11/18 (61 %)

4/18 (22 %)

.020

Duodenitis

4/18 (22 %)

2/19 (11 %)

.303

Lymphoid hyperplasia: duodenum

1/18 (6 %)

0/19 (0 %)

.486

Lymphoid hyperplasia: cecum

1/8 (13 %)

0/4 (0 %)

.667

Lymphoid hyperplasia: terminal ileum

3/14 (21 %)

0/11 (0 %)

.158

Basal plasmacytosis: rectosigmoid

2/15 (13 %)

0/14 (0 %)

.259

Basal plasmacytosis: transverse colon

1/3 (33 %)

0/4 (0 %)

.429

Basal plasmacytosis: cecum

1/8 (13 %)

0/4 (0 %)

.667

Cryptitis: colon any area

6/37 (16 %)

3/33 (9 %)

.485

Cryptitis: duodenum

2/18 (11 %)

0/19 (0 %)

.230

Cryptitis: rectosigmoid

3/15 (20 %)

1/13 (8 %)

.356

Cryptitis: left colon

0/2 (0 %)

1/3 (33 %)

.600

Cryptitis: transverse colon

1/3 (33 %)

1/4 (25 %)

.714

Cryptitis: right colon

1/3 (33 %)

0/2 (0 %)

.600

Cryptitis: terminal ileum

1/14 (7 %)

0/11 (0 %)

.560

Crypt abscess: colon any area

2/23 (9 %)

0/18 (0 %)

.495

Crypt abscess: rectosigmoid

2/15 (13 %)

0/14 (0 %)

.259

Crypt abscess: cecum

1/8 (13 %)

0/4 (0 %)

.667

Crypt distortion: colon any area

10/29 (34 %)

1/24 (4 %)

.008

Crypt distortion: rectosigmoid

2/15 (13 %)

0/14 (0 %)

.259

Crypt distortion: transverse colon

1/3 (33 %)

0/4 (0 %)

.429

Crypt distortion: right colon

2/3 (67 %)

0/2 (0 %)

.300

Crypt distortion: cecum

5/8 (63 %)

1/4 (25 %)

.273